Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations

被引:34
|
作者
Shen, Jie [1 ]
Lu, Guang Wei [2 ]
Hughes, Patrick [3 ]
机构
[1] Allergan Plc, Clin Pharmacol Nonclin & Translat Sci, 2525 Dupont Dr, Irvine, CA 92612 USA
[2] TWi Pharmaceut Inc, Ophthalm Prod Dev, Taipei, Taiwan
[3] Glaukos Corp, Appl Res, San Clemente, CA USA
关键词
formulation; ocular; pharmacokinetic; pharmacodynamic; sustained release; targeted delivery; EPISCLERAL CYCLOSPORINE IMPLANT; IN-VITRO; SUBCONJUNCTIVAL BEVACIZUMAB; SUSTAINED-RELEASE; VIVO EVALUATION; AQUEOUS-HUMOR; GLAUCOMA; PHARMACOKINETICS; LATANOPROST; ABSORPTION;
D O I
10.1007/s11095-018-2498-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] CHIRALITY - CLINICAL PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
    LEE, EJD
    WILLIAMS, KM
    CLINICAL PHARMACOKINETICS, 1990, 18 (05) : 339 - 345
  • [32] Pharmacokinetic and pharmacodynamic considerations in gene therapy
    Kamiya, H
    Akita, H
    Harashima, H
    DRUG DISCOVERY TODAY, 2003, 8 (21) : 990 - 996
  • [33] PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS FOR CHRONIC HEMODIALYSIS
    DEDRICK, RL
    KIDNEY INTERNATIONAL, 1975, 7 (01) : S7 - S15
  • [34] Pharmacokinetic and pharmacodynamic considerations of retinoids: tretinoin
    Shapiro, SS
    Latriano, L
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 39 (02) : S13 - S16
  • [35] Geriatric Psychopharmacology: Pharmacokinetic and Pharmacodynamic Considerations
    Carlo, Andrew D.
    Alpert, Jonathan E.
    PSYCHIATRIC ANNALS, 2015, 45 (07) : 336 - 341
  • [36] Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology
    Catterson, ML
    Preskorn, SH
    Martin, RL
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1997, 20 (01) : 205 - &
  • [37] Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties
    Ismail, Ayman
    Nasr, Maha
    Sammour, Omaima
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 583
  • [38] Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations
    Stott, Katharine E.
    Hope, William W.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 : I12 - I18
  • [39] Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
    Gao, Yangyang
    Xia, Yuwei
    Chen, Yixin
    Zhou, Shiqi
    Fang, Yingying
    Yu, Jieru
    Zhang, Leyin
    Sun, Leitao
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [40] Drug-Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic/Pharmacodynamic and Study Design Considerations
    Sun, Haiying
    Sivasubramanian, Rama
    Vaidya, Soniya
    Barve, Avantika
    Jarugula, Venkateswar
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 : S49 - S62